Philippines - English - FDA (Food And Drug Administration)

sanofi pasteur inc - diptheria toxoid, tetanus toxoid, b. pertussis (whole cell), hepatitis b (r-dna) surface antigen and haemophilus influenzae type b conjugate (adsorbed) (see reverse for formulation) suspension for injection (im) - suspension for injection (im) - (see reverse for formulation)

Philippines - English - FDA (Food And Drug Administration)

sanofi pasteur inc - diptheria toxoid, tetanus toxoid, b. pertussis (whole cell), hepatitis b (r-dna) surface antigen and haemophilus influenzae type b conjugate (adsorbed) (see reverse for formulation) suspension for injection (im) - suspension for injection (im) - (see reverse for formulation)

Philippines - English - FDA (Food And Drug Administration)

sanofi pasteur inc - diptheria toxoid, tetanus toxoid, b. pertussis (whole cell), hepatitis b (r-dna) surface antigen and haemophilus influenzae type b conjugate (adsorbed) - suspension for injection (im) - (see reverse for formulation)

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

biological e. limited, india - diptheria toxoid,tetanus toxoid,b.pertussis,hepatitis b surface antigen & purified capsular polysaccharide (prp) , - injection - ,

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - pertussis toxoid, quantity: 16 microgram/ml; pertussis filamentous haemagglutinin, quantity: 16 microgram/ml; pertactin, quantity: 5 microgram/ml; diphtheria toxoid, quantity: 4 iu/ml; tetanus toxoid, quantity: 40 iu/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; aluminium phosphate; sodium chloride; water for injections - boostrix is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals aged four years and older (see section 4.2 dose and method of administration).,boostrix is also indicated for passive protection against pertussis in early infancy following maternal immunisation during pregnancy (see section 4.2 dose and method of administration, section 4.6 fertility, pregnancy and lactation and 5.1 pharmacodynamic properties).,the use of boostrix should be in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - pertussis toxoid, quantity: 16 microgram/ml; tetanus toxoid, quantity: 40 iu/ml; diphtheria toxoid, quantity: 4 iu/ml; pertactin, quantity: 5 microgram/ml; pertussis filamentous haemagglutinin, quantity: 16 microgram/ml - injection, suspension - excipient ingredients: water for injections; aluminium hydroxide hydrate; aluminium phosphate; sodium chloride - boostrix is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals aged four years and older (see section 4.2 dose and method of administration).,boostrix is also indicated for passive protection against pertussis in early infancy following maternal immunisation during pregnancy (see section 4.2 dose and method of administration, section 4.6 fertility, pregnancy and lactation and 5.1 pharmacodynamic properties).,the use of boostrix should be in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - pertussis filamentous haemagglutinin, quantity: 10 microgram/ml; pertussis fimbriae 2 + 3, quantity: 10 microgram/ml; tetanus toxoid, quantity: 80 iu/ml; pertussis toxoid, quantity: 20 microgram/ml; diphtheria toxoid, quantity: 60 iu/ml; pertactin, quantity: 6 microgram/ml - injection, suspension - excipient ingredients: aluminium phosphate; water for injections; phenoxyethanol - tripacel is indciated for primary immunisation against diphtheria, tetanus and pertussis when commenced between 2 months and 12 months of age. tripacel is also indicated for the fourth and fifth dose for children from 15 months of age up to their eighth birthday who have been immunised previously with three or four doses of diphtheria, tetanus and pertussis (whole cell or acellular) vaccines.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis b surface antigen recombinant, quantity: 20 microgram/ml; pertactin, quantity: 16 microgram/ml; poliovirus, quantity: 16 dagu; pertussis filamentous haemagglutinin, quantity: 50 microgram/ml; diphtheria toxoid, quantity: 30 iu; tetanus toxoid, quantity: 40 iu; pertussis toxoid, quantity: 50 microgram/ml; poliovirus, quantity: 80 dagu; poliovirus, quantity: 64 dagu - injection, suspension - excipient ingredients: aluminium phosphate; aluminium hydroxide hydrate; polymyxin b sulfate; water for injections; sodium chloride; neomycin sulfate; glucose monohydrate; ascorbic acid; polysorbate 80; calcium chloride dihydrate; ferric nitrate nonahydrate; potassium chloride; magnesium sulfate heptahydrate; monobasic potassium phosphate; dibasic sodium phosphate; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine phosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride monohydrate; sodium hypoxanthine; ribose; sodium acetate; thymine; uracil; sodium xanthine; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; glutamine; glycine; histidine hydrochloride; isoleucine; hydroxyproline; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; dl-threonine; dl-tryptophan; tyrosine disodium; dl-valine; biotin; ergocalciferol; calcium pantothenate; choline chloride; folic acid; inositol; menadione; nicotinic acid; nicotinamide; aminobenzoic acid; pyridoxal hydrochloride; pyridoxine hydrochloride; riboflavine; thiamine hydrochloride; retinol acetate; dl-alpha-tocopheryl phosphate disodium - indications: infanrix penta is indicated for immunisation of infants from the age of 6 weeks against diphtheria, tetanus, pertussis, hepatitis b and poliomyelitis. infanrix penta may also be used as a booster dose at 18 months of age if boosting with hepatitis b and poliomyelitits, as well as diphtheria, tetanus and pertussis is required.

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - diphtheria toxoid protein; meningococcal (serogroup a) polysaccharide (monovalent conjugate); meningococcal (serogroup c) polysaccharide (monovalent conjugate); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate); meningococcal (serogroup y) polysaccharide (monovalent conjugate) - injection, solution - 48 microgram (diptheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio) - diphtheria toxoid protein 48 mcg/dose (0.5 ml) (diphtheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio); meningococcal (serogroup a) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup c) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup y) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - poliovirus, quantity: 26 dagu; poliovirus, quantity: 7 dagu; pertactin, quantity: 3 microgram; tetanus toxoid, quantity: 20 iu; diphtheria toxoid, quantity: 2 iu; pertussis toxoid, quantity: 2.5 microgram; pertussis filamentous haemagglutinin, quantity: 5 microgram; pertussis fimbriae 2 + 3, quantity: 5 microgram; poliovirus, quantity: 29 dagu - injection, suspension - excipient ingredients: aluminium phosphate; formaldehyde; polysorbate 80; neomycin; water for injections; phenoxyethanol; streptomycin sulfate; polymyxin b sulfate; glutaral; ethanol - adacel polio is indicated for active immunisation against diphtheria, tetanus, pertussis and poliomyelitis in adults, adolescents and children aged 4 years and older as a booster following primary immunisation.,children 4-6 years of age should have already received four doses of dtpa and ipv or opv.,adacel polio is not intended for primary immunisation.,adacel polio may be administered during pregnancy for prevention of pertussis in young infants via transplacental antibody transfer from the pregnant woman to the fetus.,the use of adacel polio should be determined on the basis of official recommendations. for further information, refer to the current immunisation handbook.